About the Company
We do not have any company description for SAB Biotherapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics, Inc. (SABS) is expected to deliver a year-over-year decline in earnings on higher revenues when it ...
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings ... - Nasdaq
SAB Biotherapeutics, Inc. (SABS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025.
SABSW SAB Biotherapeutics, Inc. WT EXP 102226
SAB Biotherapeutics, Inc. WT EXP 102226 SEC Filing - Quarterly Report (10-Q) August 08, 2024 SEC FilingsThu, Aug. 08, 2024 SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook ...
SABS Stock Quote Price and Forecast | CNN
View SAB Biotherapeutics, Inc. SABS stock quote prices, financial information, real-time forecasts, and company news from CNN.
SAB Biotherapeutics, Inc.: SAB Biotherapeutics Reports Full Year 2023 ...
Sioux Falls, SD, March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during ...
SAB Biotherapeutics, Inc. (SABSW) - Yahoo Finance
Get the latest SAB Biotherapeutics, Inc. (SABSW) stock news and headlines to help you in your trading and investing decisions.
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Reported Third-Quarter ...
Taking into account the latest results, the current consensus from SAB Biotherapeutics' two analysts is for revenues of US$40.2m in 2023, which would reflect a huge 23% increase on its sales over ...
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 ...
About SAB Biotherapeutics, Inc. SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs ...
SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces 1-for-10 ...
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human ...
Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best ...
SAB Biotherapeutics, Inc. (NASDAQ:SABS) is gaining attention as a top diabetes stock under $10 which was driven by its innovative lead asset, SAB-142, a disease-modifying therapy for Type 1 ...
Similar Companies
Loading the latest forecasts...